Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

RANDOMIZED PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

Intervention/treatment:
GAZYVA / VENCLEXTA
Medical condition:
CHRONIC LYMPHOCYTIC LEUKEMIA
Protocol code:
CLC.3 / S1925
Control number:
258677
Status:
Recruiting
Approved:
December 15, 2021
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT04269902
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY

Locations

British Columbia

BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
888-939-3333
Name
Alina S. Gerrie
Role
PRINCIPAL_INVESTIGATOR

Manitoba

CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
866-561-1026
Name
Versha Banerji
Role
PRINCIPAL_INVESTIGATOR

New Brunswick

Atlantic Health Sciences Corporation-Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
506-648-6890
Name
Alfonso Rivera Duarte
Role
PRINCIPAL_INVESTIGATOR

Nova Scotia

QEII Health Sciences Centre/Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 2Y9
ACTIVE_NOT_RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
902-473-6000
Name
Katherine S. Robinson
Role
PRINCIPAL_INVESTIGATOR

Ontario

Lakeridge Health Oshawa
Oshawa, Ontario, L1G 2B9
ACTIVE_NOT_RECRUITING
Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario, K1H 8L6
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
613-761-4395
Name
David A. Macdonald
Role
PRINCIPAL_INVESTIGATOR

Quebec

Jewish General Hospital
Montreal, Quebec, H3T 1E2
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
514-340-8222
Extension 8248
Name
Tanya Skamene
Role
PRINCIPAL_INVESTIGATOR

Saskatchewan

Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
ACTIVE_NOT_RECRUITING
Did you find what you were looking for?